The potential role of MR activation in LRH is important, since LRH and primary aldosteronism are similarly associated with higher risk for cardiometabolic events and death [10,11], and the availability of oral MR antagonists permits a potential targeted therapy. The gene discussed is NR3C2; the disease is primary aldosteronism.